BridgeMD
Compares treatment options for Type 2 Diabetes Mellitus
Official title A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
ClinicalTrials.gov ID: NCT07662135
What this study is testing
What is Elecoglipron?
Elecoglipron is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for type 2 diabetes mellitus.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosed with Type 2 Diabetes Mellitus for at least 90 days prior to screening
- On SGTL2i or SGLT2i-naïve and other glucose lowering medication(s)
- HbA1c value:
- On stable dose of SGLT2i ≥ 7.0 % to ≤ 10.5% (53 to 91.3 mmol/mol)
- SGLT2i-naive ≥ 7.5% to ≤ 10.5% (58 to 91.3 mmol/mol)
You likely can't join if
- Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
- Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
- Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor...
- Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
- History of acute or chronic pancreatitis
- Severe congestive heart failure (New York Heart Association IV)
See the full eligibility criteria
- Diagnosed with Type 2 Diabetes Mellitus for at least 90 days prior to screening
- On SGTL2i or SGLT2i-naïve and other glucose lowering medication(s)
- HbA1c value:
- On stable dose of SGLT2i ≥ 7.0 % to ≤ 10.5% (53 to 91.3 mmol/mol)
- SGLT2i-naive ≥ 7.5% to ≤ 10.5% (58 to 91.3 mmol/mol)
- Impaired renal function
- Body mass index (BMI) of ≥ 23 kg/m2 at screening
- Stable body weight (self-reported or documented) for 90 days prior to screening
- Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
- Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
- Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
- Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
- History of acute or chronic pancreatitis
- Severe congestive heart failure (New York Heart Association IV)
- History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
The study team makes the final eligibility decision.
Where it's taking place
- Peoria, Arizona, United States
- Surprise, Arizona, United States
- Concord, California, United States
- Sacramento, California, United States
- Victorville, California, United States
- Fleming Island, Florida, United States
- Lauderdale Lakes, Florida, United States
- Leesburg, Florida, United States
- Miami Lakes, Florida, United States
- Ocoee, Florida, United States
- Orlando, Florida, United States
- Braintree, Massachusetts, United States
- New Bedford, Massachusetts, United States
- Saint Joseph, Michigan, United States
- Saint Paul, Minnesota, United States
- Kansas City, Missouri, United States
- Omaha, Nebraska, United States
- Las Vegas, Nevada, United States
- Albuquerque, New Mexico, United States
- The Bronx, New York, United States
+ 126 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Peoria, Arizona, United States; Surprise, Arizona, United States; Concord, California, United States; Sacramento, California, United States; Victorville, California, United States; Fleming Island, Florida, United States and 140 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.